MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
Our data showed that KRAS<sup>G12D</sup> inhibitor MRTX1133 combined with PKF-118-310 could enhance the effectiveness of MRTX1133 treatment response through induction of ferroptosis via inhibiting MGST1 expression in MRTX1133-resistant PDAC cells and tumors. This evidence may provide a promising strategy to overcome KRAS<sup>G12D</sup> inhibitor MRTX1133 resistance in PDAC patients with KRAS<sup>G12D</sup> mutations.
Authors
- Weihao Lin (ORCID: https://orcid.org/0000-0002-1499-2608)
- Chungui Xu
- Yarui Ma
- Yuchen Jiao (ORCID: https://orcid.org/0000-0001-7917-8810)
- Xue Wang (ORCID: https://orcid.org/0009-0009-3062-2103)
- Guiling Zhu
- Ziyi Zhao (ORCID: https://orcid.org/0009-0008-6548-7960)
- Xiaobing Wang (ORCID: https://orcid.org/0000-0001-5044-3721)
- Qi Zhang (ORCID: https://orcid.org/0000-0003-3658-8005)
- Chunxia Du (ORCID: https://orcid.org/0000-0003-3457-6377)
- Ai Guo (ORCID: https://orcid.org/0000-0002-6918-4878)
- Weiwei Song (ORCID: https://orcid.org/0000-0002-8567-7680)
- Zhendiao Zhou
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Henan Academy of Sciences (CN)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1186/s10020-024-00972-y
- Citations
- 7
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Chinese Academy of Medical Sciences
- Cancer Foundation of China